Skip to main content

Want a detailed portfolio tracker?

Silexion Therapeutics (SLXN) Income Statement (2020 - 2026)

Income Statement report data from Dec 31, 2020 to Mar 31, 2026 for Silexion Therapeutics (SLXN).

All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.

Reported currency: USD
Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020
Revenue and COGS
Cost Of Revenue
------20K
(+100.00%)
10K------------
Costof Goods And Services Sold
------20K
(+100.00%)
10K------------
Gross Profit
-------20.00K
(+100.00%)
-10.00K------------
Operating Expenses
Research And Development
1.37M
(-59.47%)
3.38M
(+56.48%)
2.16M
(+111.76%)
1.02M
(+72.88%)
590K
(-32.18%)
870K
(-72.98%)
3.22M
(+318.18%)
770K
(-19.79%)
960K
(-23.81%)
1.26M
(+133.33%)
540K---------
Selling General And Administrative
1.38M
(+33.98%)
1.03M
(-8.85%)
1.13M
(-10.32%)
1.26M
(+18.87%)
1.06M
(+2.91%)
1.03M
(-78.54%)
4.80M
(+686.89%)
610K
(+117.86%)
280K
(-40.43%)
470K
(+147.37%)
190K---------
Operating Expenses
2.75M-18.86M3.29M
(+44.30%)
2.28M
(+38.18%)
1.65M
(-13.16%)
1.90M
(-76.28%)
8.01M
(+480.43%)
1.38M
(+10.40%)
1.25M
(-27.75%)
1.73M
(+136.99%)
730K
(+48.98%)
490K
(+104.17%)
240K
(+50.00%)
160K
(-54.29%)
350K
(-18.60%)
430K-200K
(+122.22%)
90K
(-55.00%)
200K
Depreciation And Amortization
------20K
(+100.00%)
10K
(0.00%)
10K
(0.00%)
10K
(0.00%)
10K---------
Operating Income
Operating Income
-2.75M19M-3.29M
(+44.30%)
-2.28M
(+38.18%)
-1.65M
(-13.16%)
-1.90M
(-76.37%)
-8.04M
(+482.61%)
-1.38M
(+10.40%)
-1.25M
(-27.75%)
-1.73M
(+136.99%)
-730.00K
(+48.98%)
-490.00K
(+104.17%)
-240.00K
(+50.00%)
-160.00K
(-54.29%)
-350.00K
(-18.60%)
-430.00K--200.00K
(+122.22%)
-90.00K
(-55.00%)
-200.00K
Ebit
-2.73M
(-38.10%)
-4.41M
(+35.28%)
-3.26M
(+30.40%)
-2.50M
(+44.51%)
-1.73M
(+8550.00%)
-20.00K
(-99.83%)
-11.81M
(+697.97%)
-1.48M
(+4.23%)
-1.42M
(-14.97%)
-1.67M
(+108.75%)
-800.00K
(+63.27%)
-490.00K
(+104.17%)
-240.00K
(+50.00%)
-160.00K
(-54.29%)
-350.00K
(-18.60%)
-430.00K--200.00K
(+122.22%)
-90.00K
(-55.00%)
-200.00K
EBITDA
-2.73M
(-37.95%)
-4.40M
(+34.97%)
-3.26M
(+30.40%)
-2.50M
(+45.35%)
-1.72M
(-1.71%)
-1.75M
(-85.14%)
-11.78M
(+695.95%)
-1.48M
(+4.96%)
-1.41M
(-15.57%)
-1.67M
(+111.39%)
-790.00K490K
(+68.97%)
290K
(+625.00%)
40K-250.00K
(+4.17%)
-240.00K
(+9.09%)
-220.00K
(+15.79%)
-190.00K
(+90.00%)
-100.00K
(-50.00%)
-200.00K
Other Income / Expenses
Interest Income
30K
(-57.14%)
70K
(+75.00%)
40K
(0.00%)
40K-20K-10K
(-50.00%)
20K
(-33.33%)
30K
(-25.00%)
40K---------
Interest Expense
-10K--10K-50K--40K----------
Net Interest Income
40K
(-87.10%)
310K
(+416.67%)
60K
(+50.00%)
40K-90.00K
(+200.00%)
-30.00K
(-99.38%)
-4.84M-20K
(-75.00%)
80K----------
Net Income
Income Before Tax
-2.73M
(-38.10%)
-4.41M
(+35.28%)
-3.26M
(+30.40%)
-2.50M
(+44.51%)
-1.73M
(-1.14%)
-1.75M
(-85.24%)
-11.86M
(+695.97%)
-1.49M
(+4.93%)
-1.42M
(-14.97%)
-1.67M
(+108.75%)
-800.00K490K
(+68.97%)
290K
(+625.00%)
40K-250.00K
(+4.17%)
-240.00K
(+9.09%)
-220.00K
(+15.79%)
-190.00K
(+90.00%)
-100.00K
(-50.00%)
-200.00K
Income Tax Expense
--------10K
(0.00%)
10K
(0.00%)
10K---------
Net Income From Continuing Operations
-2.73M
(-38.10%)
-4.41M
(+35.28%)
-3.26M
(+30.40%)
-2.50M
(+44.51%)
-1.73M
(-1.14%)
-1.75M
(-85.24%)
-11.86M
(+695.97%)
-1.49M
(+4.93%)
-1.42M
(-15.48%)
-1.68M
(+107.41%)
-810.00K---------
Net Income
-2.73M
(-38.10%)
-4.41M
(+35.28%)
-3.26M
(+30.40%)
-2.50M
(+44.51%)
-1.73M
(-1.14%)
-1.75M
(-85.23%)
-11.85M
(+706.12%)
-1.47M
(+7.30%)
-1.37M
(-20.81%)
-1.73M
(+118.99%)
-790.00K490K
(+68.97%)
290K
(+625.00%)
40K-250.00K
(+4.17%)
-240.00K
(+9.09%)
-220.00K
(+15.79%)
-190.00K
(+90.00%)
-100.00K
(-50.00%)
-200.00K